Chennai: Researchers have devoted a novel approach to ‘purify’ the immune cells of patients in the fight against cancer.
CAR-T biotherapeutics company Carina Biotech and researchers at the University of South Australia have developed a new approach based on microfluidic technology.
UniSA’s Future Industries Institute PhD student Mona Elsemary has developed the approach to purify chimeric antigen receptor (CAR-T) cells, the bioengineered immune cells that are the basis of groundbreaking cellular immunotherapy—a transformative cancer therapy that harnesses the power of a patient’s immune system to fight their cancer.
Elsemary’s work is part of Carina Biotech’s CAR-T development platform, which aims to produce effective treatments for solid cancers. The study was Elsemary presented at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy.
Elsemary said, “CAR-T therapy has produced some remarkable results against blood cancers and there is a huge international research effort underway to transform this success into producing CAR-T treatments for solid cancers.”